Compositions and methods for hematopoietic stem cell transplants
AssigneeOrca Biosystems, Inc.
InventorsIvan Dimov, Nathaniel Fernhoff, Kevin Sheehan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional αβ-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.
Claims20
A method of treating a human subject in need thereof, the method comprising
- administering to the human subject a pharmaceutical composition comprising one or more unit doses of a cellular graft,
- wherein each unit dose of the cellular graft comprises populations of therapeutic cells for each kilogram (kg) of body weight of a subject receiving the cellular graft, and
- wherein the populations of therapeutic cells of each unit dose comprise:
- more than 3×105 hematopoietic stem/progenitor cells (HSPC) per kilogram of body weight of the subject receiving the cellular graft,
- more than 3×105 memory T cells (Tmem) per kilogram of body weight of the subject receiving the cellular graft,
- more than 5×105 regulatory T cells (Treg) per kilogram of body weight of the subject receiving the cellular graft, and
- less than 3×105 naïve conventional αβ-T cells per kilogram of body weight of the subject receiving the cellular graft.
A method of treating a human subject in need thereof, the method comprising
- administering to the human subject a pharmaceutical composition comprising a population of therapeutic cells that is enriched for hematopoietic stem/progenitor cells (HSPC), memory T cells (Tmem), and regulatory T cells (Treg),
- wherein the population of cells is depleted of naïve conventional αβ-T cells, and
- wherein the population of therapeutic cells comprises a ratio of naive conventional αβ-T cells to HSPC that is less than 1:400, a ratio of naïve conventional αβ-T cells to Tmem that is less than 1:800, and a ratio of naïve conventional αβ-T cells to Treg that is less than 1:5.
Dependencies are inferred from the claim text.